Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third quarter ended 30th September 2005 (Q3 2005) and nine months ended 30th September 2005.
Accounting Standard: International Financial Reporting Standards (IFRS).
Key Context: GSK reported strong pharmaceutical sales growth driven by key products Advair, Avandia, and Vaccines. The company raised its full-year 2005 earnings guidance to "mid-teens" EPS percentage growth in constant exchange rate (CER) terms.
Key Financial Metrics
| Metric | Q3 2005 (£m) | Q3 2004 (£m) | CER Growth % | 9 Months 2005 (£m) | 9 Months 2004 (£m) | CER Growth % |
|---|---|---|---|---|---|---|
| Turnover | 5,471 | 4,924 | 9% | 15,753 | 14,750 | 7% |
| Operating Profit | 1,783 | 1,497 | 14% | 5,241 | 4,515 | 15% |
| Profit Before Tax | 1,753 | 1,451 | 16% | 5,126 | 4,457 | 14% |
| Profit After Tax | 1,253 | 1,047 | 15% | 3,665 | 3,221 | 13% |
| Earnings Per Share (Basic) | 21.3p | 17.7p | 16% | 62.8p | 54.6p | 14% |
| Operating Margin | 32.6% | 30.4% | +2.2 pts | 33.3% | 30.6% | +2.7 pts |
Cash Flow (Q3 2005): Net cash inflow from operating activities was £1,856 million. Net cash outflow from investing activities was £246 million. Net cash outflow from financing activities was £861 million (primarily due to dividends and share buybacks).
Net Debt: Reduced to £399 million at 30th September 2005 (from £1,984 million at 31st December 2004).
Dividend: Third interim dividend declared at 10 pence per share.
Material Changes vs. Prior Period
- Revenue Growth: Total turnover grew 9% (CER) in Q3, driven by a 10% (CER) increase in Pharmaceutical sales to £4.7 billion. Consumer Healthcare sales grew 3% (CER).
- Profitability: Operating profit grew 14% (CER), outpacing sales growth due to cost of sales increasing only 6% and gains from asset disposals (£122 million in Q3 vs £4 million in Q3 2004).
- Expense Increases: Selling, general and administration (SG&A) expenses rose 13% (CER), and R&D expenses rose 15% (CER). SG&A included £190 million in legal costs (up from £121 million in Q3 2004) and £29 million in cost-saving programme charges.
- Product Performance:
- Advair/Seretide: Sales up 20% to £737 million.
- Avandia/Avandamet: Sales up 22% to £355 million.
- Vaccines: Sales up 20% to £399 million, with US sales surging 82%.
- Paxil: Sales fell 44% to £142 million due to generic competition.
Guidance, Outlook, Risks, and Unusual Items
Guidance and Outlook
GSK raised its full-year 2005 earnings guidance to "mid-teens" EPS percentage growth in CER terms, up from previous "low double-digit" guidance. Management expects strong performance to continue into the fourth quarter.
Strategic Moves and Pipeline
- Vaccines Expansion: Committed approximately $2 billion to strengthen the vaccines business, including the proposed acquisition of ID Biomedical Corporation for ~$1.4 billion and the purchase of a vaccine R&D facility in Pennsylvania.
- Pandemic Preparedness: Developing an H5N1 prototype pandemic vaccine and expanding capacity for Relenza (antiviral) due to increased demand.
- Pipeline: FDA recommended accelerated approval for Arranon (leukaemia/lymphoma). Cervarix (HPV vaccine) Phase III data received. Clinical trials for aplaviroc (HIV) terminated due to hepatotoxicity reports.
Risks and Contingencies
- Legal Matters: Aggregate provision for legal and other disputes (excluding tax) was just over £1.1 billion. Significant litigation includes product liability, intellectual property challenges (e.g., Zofran, Wellbutrin XL), and government investigations.
- Tax Disputes: Ongoing disputes with the US IRS regarding transfer pricing for years 1989-2000, with total claims of $8.2 billion (taxes and interest). A trial is scheduled for October 2006.
- Regulatory: European Commission initiated an inspection regarding allegations of abuse of dominant position concerning paroxetine (Seroxat) in Europe.
- Manufacturing: Production at the Cidra, Puerto Rico facility resumed after corrective actions for cGMP issues.
Investor Verification Checklist
- Guidance Sustainability: Verify if "mid-teens" EPS growth is achievable given the strong Q3 performance and potential Q4 currency headwinds.
- Legal Provisions: Monitor the £1.1 billion legal provision and the outcome of the US Tax Court trial scheduled for October 2006 regarding the $8.2 billion tax claim.
- Patent Expirations: Assess the impact of generic competition on Paxil and the status of patent litigation for Zofran and Wellbutrin XL.
- Vaccine Acquisitions: Track the regulatory approval and closing of the ID Biomedical Corporation acquisition (~$1.4 billion).
- Share Buybacks: Review the remaining capacity of the £4 billion share buy-back programme (£2.199 billion used by end of 2004, plus £638 million in 9 months 2005).